Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Aberg

Showing results (311-320 of 424) with videos related to

Pageof 43
Sort By:
Frontiers in Immunology|June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE studyJosep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Human Molecular Genetics|October 19, 2013
A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjectsJoseph L McClay, Karolina A Aberg, Shaunna L Clark, et al.
Infectious Diseases and Therapy|September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Epigenomics|December 19, 2012
MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case--control samplesKarolina A Aberg, Joseph L McClay, Srilaxmi Nerella, et al.
Biological Psychiatry|January 1, 2020
Cell Type-Specific Methylome-wide Association Studies Implicate Neurotrophin and Innate Immune Signaling in Major Depressive DisorderRobin F Chan, Gustavo Turecki, Andrey A Shabalin, et al.
The Journal of Infectious Diseases|November 18, 2021
COVID-19 Vaccination Rates in a Global HIV CohortEvelynne S Fulda, Kathleen V Fitch, Edgar T Overton, et al.
Plos One|February 10, 2017
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN CohortAllison L Agwu, John A Fleishman, Guy Mahiane, et al.
Annals of Internal Medicine|October 3, 2000
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study TeamJ S Currier, P L Williams, S L Koletar, et al.
JAMA|July 24, 2012
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelMelanie A Thompson, Judith A Aberg, Jennifer F Hoy, et al.
Pageof 43

Showing results (311-320 of 424) with videos related to

Sort By:
Pageof 43
Frontiers in Immunology|June 12, 2024
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE studyJosep M Llibre, Judith A Aberg, Sharon Walmsley, et al.
Plos One|February 13, 2023
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials GroupUmesh G Lalloo, Lauren Komarow, Judith A Aberg, et al.
Human Molecular Genetics|October 19, 2013
A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjectsJoseph L McClay, Karolina A Aberg, Shaunna L Clark, et al.
Infectious Diseases and Therapy|September 26, 2023
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1Judith A Aberg, Bronagh Shepherd, Marcia Wang, et al.
Epigenomics|December 19, 2012
MBD-seq as a cost-effective approach for methylome-wide association studies: demonstration in 1500 case--control samplesKarolina A Aberg, Joseph L McClay, Srilaxmi Nerella, et al.
Biological Psychiatry|January 1, 2020
Cell Type-Specific Methylome-wide Association Studies Implicate Neurotrophin and Innate Immune Signaling in Major Depressive DisorderRobin F Chan, Gustavo Turecki, Andrey A Shabalin, et al.
The Journal of Infectious Diseases|November 18, 2021
COVID-19 Vaccination Rates in a Global HIV CohortEvelynne S Fulda, Kathleen V Fitch, Edgar T Overton, et al.
Plos One|February 10, 2017
Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN CohortAllison L Agwu, John A Fleishman, Guy Mahiane, et al.
Annals of Internal Medicine|October 3, 2000
Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study TeamJ S Currier, P L Williams, S L Koletar, et al.
JAMA|July 24, 2012
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelMelanie A Thompson, Judith A Aberg, Jennifer F Hoy, et al.
Pageof 43